OCU400 positioned as potential one-time gene therapy, Ocugen, Inc. moves toward regulatory filing

OCU400 positioned as potential one-time gene therapy, Ocugen, Inc. moves toward regulatory filing
Ocugen, Inc. advances OCU400 therapy

Ocugen, Inc. is progressing OCU400, a gene therapy designed to address multiple mutations causing retinitis pigmentosa, toward a planned Biologics License Application (BLA) submission this year.

The therapy is distinguished by its aim to treat various genetic forms of the condition through a single, potentially one-time administration. Ocugen, Inc. continues to provide updates as the development moves closer to regulatory review.

Ocugen previously launched a modifier gene therapy platform targeting inherited blindness and presented updates at three industry conferences, according to an earlier summary here. The company has also advanced an early-stage gene therapy for Stargardt disease, addressing a patient group lacking FDA-approved treatments here. These initiatives position Ocugen among firms developing solutions for advanced retinal diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.